Skip to main content
OpenTrials
Completed

NCT Number: NCT02288585

The Effect of Plant Sterols on the Blood Lipid Profile of Subjects With and at High Risk of Type 2 Diabetes Mellitus

Double-blind, randomised, placebo-controlled, parallel group study with two intervention arms. The study will be conducted in 150 subjects and the primary objective is to show a fasting LDL-cholesterol and triglyceride lowering effect of plant sterols in subjects with established type 2 diabetes mellitus and subjects at high risk of developing type 2 diabetes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

30 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CSIRO, Adelaide, Australia

Loading trial locations.

About this study

The main aim of the study is to investigate the effect of plant sterols on fasting triglycerides and LDL-cholesterol concentrations.

This study also aims to study the effect of plant sterols on fasting total cholesterol, HDL-cholesterol concentrations and Lipoprotein (a). Furthermore the effects of plant sterols on fasting blood glucose and insulin will be explored. At last, in a sub-group, at end of intervention the acute, chronic and acute upon chronic effect of plant sterols on postprandial blood lipids, glucose and insulin responses during a mixed meal challenge rich in fat and carbohydrates will be explored.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Triglycerides >150 mg/dL or 1.74 mmol/L
  • LDL-cholesterol: Subjects at high risk for developing T2DM: 115-190 mg/dL or 2.95-4.94 mmol/L. Subjects with established T2DM that are on statins: 85-190 mg/dL or 2.15-4.94 mmol/L.
  • HbA1c: Subjects at high risk for developing T2DM: <6.50% or ≥ 48 mmol/mol. Subjects with established T2DM: ≤ 8.5% or ≤ 69 mmol/mol.
  • BMI > 20.0 kg/m2.

Exclusion criteria

  • Recently (within 1 year) diagnosed with cardiovascular event(s) (stroke, TIA, angina, myocardial infarction, heart failure), systemic inflammatory conditions
  • Use of over-the-counter and prescribed medication which may interfere with study measurements (i.e. ezetimibe, fibrates and Niacin), to be judged by the principal investigator.
  • Currently smoking or being a non-smoker for less than 6 months and reported use of any nicotine containing products in the 6 months prior to screening and/or during the study.

Treatment and study plan

Plant Sterols

Dietary Supplement

Plant sterols

Placebo product

Dietary Supplement

Placebo product

Primary outcomes

  1. Change in TG concentrations

    Time frame: At baseline (after 2 weeks run-in period) and after 6 weeks intervention

  2. Change in LDL-C

    Time frame: At baseline (after 2 weeks run-in period) and after 6 weeks intervention

Secondary outcomes

  1. Change in blood lipids

    Time frame: At baseline (after 2 weeks run-in period) and after 6 weeks intervention

Other outcomes

  1. Change in blood glucose

    Time frame: At baseline (after 2 weeks run-in period) and after 6 weeks intervention

  2. Change in insulin

    Time frame: At baseline (after 2 weeks run-in period) and after 6 weeks intervention

  3. Acute, chronic and acute upon chronic effect on postprandial lipids, glucose and insulin

    Time frame: At the end of intervention (after 6 weeks)

    In a sub-group (n=48) of the population

  4. Change in Advanced Glycation End products (AGEs)

    Time frame: At baseline (after 2 weeks run-in period) and after 6 weeks intervention

Sponsors and collaborators

Lead sponsor

Unilever R&D

Industry

Collaborators

  • Commonwealth Scientific and Industrial Research Organisation, Australia

Registry information

Official study title

The Effect of a Low-fat Spread Enriched With Plant Sterol Esters on the Blood Lipid Profile of Subjects With Established Type 2 Diabetes Mellitus and Subjects at High Risk of Developing Type 2 Diabetes

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Nov 11, 2014
Registry last updated
Jan 19, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.